Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Buy
67
XERS Quote, Financials, Valuation and Earnings
Last price:
$4.88
Seasonality move
:
47.77%
Day range:
$5.00 - $5.20
52-week range:
$1.69 - $6.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.72x
P/B ratio:
--
Volume:
3M
Avg. volume:
3.8M
1-year change:
146.41%
Market cap:
$792.8M
Revenue:
$203.1M
EPS (TTM):
-$0.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$57.6M | -$0.04 | 41.76% | -71.43% | $6.08 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.27 |
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$17M | -$0.28 | 16.58% | -42.86% | $17.45 |
|
TGTX
TG Therapeutics
|
$117.1M | $0.16 | 84.44% | -95.36% | $43.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$5.15 | $6.08 | $792.8M | -- | $0.00 | 0% | 3.72x |
|
ADMA
ADMA Biologics
|
$20.23 | $25.27 | $4.8B | 24.67x | $0.00 | 0% | 11.52x |
|
CARA
Cara Therapeutics
|
$5.10 | $12.00 | $23.3M | -- | $0.00 | 0% | 3.26x |
|
OCGN
Ocugen
|
$0.69 | $6.75 | $201.2M | -- | $0.00 | 0% | 46.04x |
|
OCUL
Ocular Therapeutix
|
$7.34 | $17.45 | $1.2B | -- | $0.00 | 0% | 18.23x |
|
TGTX
TG Therapeutics
|
$39.82 | $43.00 | $6.3B | 284.43x | $0.00 | 0% | 18.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
114.63% | -0.360 | 45.82% | 1.12x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
CARA
Cara Therapeutics
|
-- | -3.140 | -- | 10.67x |
|
OCGN
Ocugen
|
49.18% | 1.424 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 2.429 | 5.09% | 10.26x |
|
TGTX
TG Therapeutics
|
52.36% | 1.750 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$50.6M | $1.7M | -26.85% | -1019.2% | 4.31% | $1.8M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Xeris Biopharma Holdings vs. Competitors
-
Which has Higher Returns XERS or ADMA?
ADMA Biologics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of 95.19%. Xeris Biopharma Holdings's return on equity of -1019.2% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About XERS or ADMA?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 21.36%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 24.93%. Given that ADMA Biologics has higher upside potential than Xeris Biopharma Holdings, analysts believe ADMA Biologics is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 ADMAADMA Biologics4 0 0 -
Is XERS or ADMA More Risky?
Xeris Biopharma Holdings has a beta of 1.094, which suggesting that the stock is 9.436% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock XERS or ADMA?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or ADMA?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Xeris Biopharma Holdings's net income of -$5.1M is lower than ADMA Biologics's net income of $111.9M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 24.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.72x versus 11.52x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings3.72x -- $60.1M -$5.1M ADMAADMA Biologics11.52x 24.67x $117.5M $111.9M
-
Which has Higher Returns XERS or CARA?
Cara Therapeutics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -527.77%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Cara Therapeutics's return on equity of -374.56%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M CARACara Therapeutics70.96% -$1.73 -$4.6M -
What do Analysts Say About XERS or CARA?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 21.36%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 135.29%. Given that Cara Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Cara Therapeutics is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 CARACara Therapeutics0 1 0 -
Is XERS or CARA More Risky?
Xeris Biopharma Holdings has a beta of 1.094, which suggesting that the stock is 9.436% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.556%.
-
Which is a Better Dividend Stock XERS or CARA?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or CARA?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Xeris Biopharma Holdings's net income of -$5.1M is higher than Cara Therapeutics's net income of -$7.7M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.72x versus 3.26x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings3.72x -- $60.1M -$5.1M CARACara Therapeutics3.26x -- $1.5M -$7.7M
-
Which has Higher Returns XERS or OCGN?
Ocugen has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -1816.75%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About XERS or OCGN?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 21.36%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 879.68%. Given that Ocugen has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocugen is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 OCGNOcugen2 0 0 -
Is XERS or OCGN More Risky?
Xeris Biopharma Holdings has a beta of 1.094, which suggesting that the stock is 9.436% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.
-
Which is a Better Dividend Stock XERS or OCGN?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or OCGN?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocugen quarterly revenues of $764K. Xeris Biopharma Holdings's net income of -$5.1M is higher than Ocugen's net income of -$13.9M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.72x versus 46.04x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings3.72x -- $60.1M -$5.1M OCGNOcugen46.04x -- $764K -$13.9M
-
Which has Higher Returns XERS or OCUL?
Ocular Therapeutix has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -283.27%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About XERS or OCUL?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 21.36%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.45 which suggests that it could grow by 137.8%. Given that Ocular Therapeutix has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocular Therapeutix is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 OCULOcular Therapeutix5 0 0 -
Is XERS or OCUL More Risky?
Xeris Biopharma Holdings has a beta of 1.094, which suggesting that the stock is 9.436% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.
-
Which is a Better Dividend Stock XERS or OCUL?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or OCUL?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Xeris Biopharma Holdings's net income of -$5.1M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.72x versus 18.23x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings3.72x -- $60.1M -$5.1M OCULOcular Therapeutix18.23x -- $17.1M -$48.4M
-
Which has Higher Returns XERS or TGTX?
TG Therapeutics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of 21.57%. Xeris Biopharma Holdings's return on equity of -1019.2% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About XERS or TGTX?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 21.36%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 24.06%. Given that TG Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe TG Therapeutics is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 TGTXTG Therapeutics5 0 0 -
Is XERS or TGTX More Risky?
Xeris Biopharma Holdings has a beta of 1.094, which suggesting that the stock is 9.436% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.
-
Which is a Better Dividend Stock XERS or TGTX?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or TGTX?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Xeris Biopharma Holdings's net income of -$5.1M is lower than TG Therapeutics's net income of $23.3M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 284.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.72x versus 18.96x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings3.72x -- $60.1M -$5.1M TGTXTG Therapeutics18.96x 284.43x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
